Merck & Co., Inc.
corporate_fare Company Profile
Merck & Co., Inc. (NYSE:MRK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 66 items for MRK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for MRK spans 10-Q.
Recent high-impact activity:
- FDA Accepts Priority Review for Merck's SAC-TMT, Sets June 2027 PDUFA
- Merck's TROP2 ADC Cuts Death Risk 32% in Endometrial Cancer; FDA Sets June 2027 PDUFA
- Intismeran Plus Keytruda Cuts Recurrence or Death Risk 42% in Phase 3 Trial
- Merck's SAC-TMT Phase 3 Shows Improved Survival in Endometrial Cancer at ESMO
- First Keytruda Biosimilar Accepted for FDA Review, Threatening Merck's Blockbuster
Financial Snapshot
Short Interest & Short Volume
2.97 days to coverFINRA reported short interest of 26,825,098 shares in MRK as of the October 15, 2026 settlement, a 5.1% decrease from the prior period — about 3.0 days to cover at its recent average daily volume. On October 27, 2026, 36.6% of MRK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for MRK, detected from its recent SEC filings · based on capital-structure filings through 2026-05-20.
Debt Offering Finalized · Refinancing Acquisition Debt
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →